Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau

Research output: Contribution to journalJournal articlepeer-review

Standard

Effect of early measles vaccine on pneumococcal colonization : A randomized trial from Guinea-Bissau. / Skadkær Hansen, Nadja; Byberg, Stine; Hervig Jacobsen, Lars; Bjerregaard-Andersen, Morten; Jensen, Aksel Karl Georg; Martins, Cesario; Aaby, Peter; Skov Jensen, Jørgen; Benn, Christine Stabell; Whittle, Hilton.

In: PLOS ONE, Vol. 12, No. 5, e0177547, 17.05.2017, p. 1-15.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Skadkær Hansen, N, Byberg, S, Hervig Jacobsen, L, Bjerregaard-Andersen, M, Jensen, AKG, Martins, C, Aaby, P, Skov Jensen, J, Benn, CS & Whittle, H 2017, 'Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau', PLOS ONE, vol. 12, no. 5, e0177547, pp. 1-15. https://doi.org/10.1371/journal.pone.0177547

APA

Skadkær Hansen, N., Byberg, S., Hervig Jacobsen, L., Bjerregaard-Andersen, M., Jensen, A. K. G., Martins, C., Aaby, P., Skov Jensen, J., Benn, C. S., & Whittle, H. (2017). Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau. PLOS ONE, 12(5), 1-15. [e0177547]. https://doi.org/10.1371/journal.pone.0177547

Vancouver

Skadkær Hansen N, Byberg S, Hervig Jacobsen L, Bjerregaard-Andersen M, Jensen AKG, Martins C et al. Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau. PLOS ONE. 2017 May 17;12(5):1-15. e0177547. https://doi.org/10.1371/journal.pone.0177547

Author

Skadkær Hansen, Nadja ; Byberg, Stine ; Hervig Jacobsen, Lars ; Bjerregaard-Andersen, Morten ; Jensen, Aksel Karl Georg ; Martins, Cesario ; Aaby, Peter ; Skov Jensen, Jørgen ; Benn, Christine Stabell ; Whittle, Hilton. / Effect of early measles vaccine on pneumococcal colonization : A randomized trial from Guinea-Bissau. In: PLOS ONE. 2017 ; Vol. 12, No. 5. pp. 1-15.

Bibtex

@article{7b5ebb5f6358485b9e0aac1ade66aa89,
title = "Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau",
abstract = "Background: Measles vaccine (MV) may have non-specific beneficial effects for child health and particularly seems to prevent respiratory infections. Streptococcus pneumoniae is the leading cause of bacterial pneumonia among children worldwide, and nasopharyngeal colonization precedes infection. Objective: We investigated whether providing early MV at 18 weeks of age reduced pneumococcal colonization and/or density up to 9 months of age. Method: The study was conducted in 2013-2014 in Guinea-Bissau. Pneumococcal vaccine was not part of the vaccination program. Infants aged 18 weeks were block-randomized 2:1 to early or no early MV; at age 9 months, all children were offered MV as per current policy. Nasopharyngeal swabs were taken at baseline, age 6.5 months, and age 9 months. Pneumococcal density was determined by q-PCR. Prevalence ratios of pneumococcal colonization and recent antibiotic treatment (yes/no) by age 6.5 months (PR6.5) and age 9 months (PR9) were estimated using Poisson regression with robust variance estimates while the pneumococcal geometric mean ratio (GMR6.5 and GMR9) was obtained using OLS regression. Results: Analyses included 512 children; 346 early MV-children and 166 controls. At enrolment, the pneumococcal colonization prevalence was 80% (411/512). Comparing early MV-children with controls, the PR6.5 was 1.02 (95%CI = 0.94-1.10), and the PR9 was 1.04 (0.96-1.12). The GMR6.5 was 1.02 (0.55-1.89), and the GMR9 was 0.69 (0.39-1.21). Early MV-children tended to be less frequently treated with antibiotics prior to follow up (PR6.5 0.60 (0.34-1.05) and PR9 0.87 (0.50-1.53)). Antibiotic treatment was associated with considerably lower colonization rates, PR6.5 0.85 (0.71-1.01) and PR9 0.66 (0.52-0.84), as well as lower pneumococcal density, GMR6.5 0.32 (0.12-0.86) and GMR9 0.52 (0.18-1.52). Conclusion: Early MV at age 18 weeks had no measurable effect on pneumococcal colonization prevalence or density. Higher consumption of antibiotics among controls may have blurred an effect of early MV.",
author = "{Skadk{\ae}r Hansen}, Nadja and Stine Byberg and {Hervig Jacobsen}, Lars and Morten Bjerregaard-Andersen and Jensen, {Aksel Karl Georg} and Cesario Martins and Peter Aaby and {Skov Jensen}, J{\o}rgen and Benn, {Christine Stabell} and Hilton Whittle",
year = "2017",
month = may,
day = "17",
doi = "10.1371/journal.pone.0177547",
language = "English",
volume = "12",
pages = "1--15",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - Effect of early measles vaccine on pneumococcal colonization

T2 - A randomized trial from Guinea-Bissau

AU - Skadkær Hansen, Nadja

AU - Byberg, Stine

AU - Hervig Jacobsen, Lars

AU - Bjerregaard-Andersen, Morten

AU - Jensen, Aksel Karl Georg

AU - Martins, Cesario

AU - Aaby, Peter

AU - Skov Jensen, Jørgen

AU - Benn, Christine Stabell

AU - Whittle, Hilton

PY - 2017/5/17

Y1 - 2017/5/17

N2 - Background: Measles vaccine (MV) may have non-specific beneficial effects for child health and particularly seems to prevent respiratory infections. Streptococcus pneumoniae is the leading cause of bacterial pneumonia among children worldwide, and nasopharyngeal colonization precedes infection. Objective: We investigated whether providing early MV at 18 weeks of age reduced pneumococcal colonization and/or density up to 9 months of age. Method: The study was conducted in 2013-2014 in Guinea-Bissau. Pneumococcal vaccine was not part of the vaccination program. Infants aged 18 weeks were block-randomized 2:1 to early or no early MV; at age 9 months, all children were offered MV as per current policy. Nasopharyngeal swabs were taken at baseline, age 6.5 months, and age 9 months. Pneumococcal density was determined by q-PCR. Prevalence ratios of pneumococcal colonization and recent antibiotic treatment (yes/no) by age 6.5 months (PR6.5) and age 9 months (PR9) were estimated using Poisson regression with robust variance estimates while the pneumococcal geometric mean ratio (GMR6.5 and GMR9) was obtained using OLS regression. Results: Analyses included 512 children; 346 early MV-children and 166 controls. At enrolment, the pneumococcal colonization prevalence was 80% (411/512). Comparing early MV-children with controls, the PR6.5 was 1.02 (95%CI = 0.94-1.10), and the PR9 was 1.04 (0.96-1.12). The GMR6.5 was 1.02 (0.55-1.89), and the GMR9 was 0.69 (0.39-1.21). Early MV-children tended to be less frequently treated with antibiotics prior to follow up (PR6.5 0.60 (0.34-1.05) and PR9 0.87 (0.50-1.53)). Antibiotic treatment was associated with considerably lower colonization rates, PR6.5 0.85 (0.71-1.01) and PR9 0.66 (0.52-0.84), as well as lower pneumococcal density, GMR6.5 0.32 (0.12-0.86) and GMR9 0.52 (0.18-1.52). Conclusion: Early MV at age 18 weeks had no measurable effect on pneumococcal colonization prevalence or density. Higher consumption of antibiotics among controls may have blurred an effect of early MV.

AB - Background: Measles vaccine (MV) may have non-specific beneficial effects for child health and particularly seems to prevent respiratory infections. Streptococcus pneumoniae is the leading cause of bacterial pneumonia among children worldwide, and nasopharyngeal colonization precedes infection. Objective: We investigated whether providing early MV at 18 weeks of age reduced pneumococcal colonization and/or density up to 9 months of age. Method: The study was conducted in 2013-2014 in Guinea-Bissau. Pneumococcal vaccine was not part of the vaccination program. Infants aged 18 weeks were block-randomized 2:1 to early or no early MV; at age 9 months, all children were offered MV as per current policy. Nasopharyngeal swabs were taken at baseline, age 6.5 months, and age 9 months. Pneumococcal density was determined by q-PCR. Prevalence ratios of pneumococcal colonization and recent antibiotic treatment (yes/no) by age 6.5 months (PR6.5) and age 9 months (PR9) were estimated using Poisson regression with robust variance estimates while the pneumococcal geometric mean ratio (GMR6.5 and GMR9) was obtained using OLS regression. Results: Analyses included 512 children; 346 early MV-children and 166 controls. At enrolment, the pneumococcal colonization prevalence was 80% (411/512). Comparing early MV-children with controls, the PR6.5 was 1.02 (95%CI = 0.94-1.10), and the PR9 was 1.04 (0.96-1.12). The GMR6.5 was 1.02 (0.55-1.89), and the GMR9 was 0.69 (0.39-1.21). Early MV-children tended to be less frequently treated with antibiotics prior to follow up (PR6.5 0.60 (0.34-1.05) and PR9 0.87 (0.50-1.53)). Antibiotic treatment was associated with considerably lower colonization rates, PR6.5 0.85 (0.71-1.01) and PR9 0.66 (0.52-0.84), as well as lower pneumococcal density, GMR6.5 0.32 (0.12-0.86) and GMR9 0.52 (0.18-1.52). Conclusion: Early MV at age 18 weeks had no measurable effect on pneumococcal colonization prevalence or density. Higher consumption of antibiotics among controls may have blurred an effect of early MV.

U2 - 10.1371/journal.pone.0177547

DO - 10.1371/journal.pone.0177547

M3 - Journal article

C2 - 28545041

AN - SCOPUS:85019891916

VL - 12

SP - 1

EP - 15

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 5

M1 - e0177547

ER -

ID: 196436803